Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ARHGAP42 antisense RNA 1 (ARHGAP42-AS1) is a long non-coding antisense RNA transcribed from the opposite strand of the ARHGAP42 locus on human chromosome 11. As an antisense RNA, ARHGAP42-AS1 is likely involved in the regulation of its sense gene ARHGAP42, which encodes a Rho GTPase-activating protein important for vascular tone and cell migration. Antisense RNAs, including ARHGAP42-AS1, function primarily as regulators of gene expression at the transcriptional and post-transcriptional levels, often by affecting chromatin states, transcription initiation/elongation, or stability of sense transcripts. Although antisense RNAs are increasingly recognized as relevant to disease pathogenesis, and ARHGAP42-AS1 may have a role in cancer biology through regulation of ARHGAP42 (for example, influencing cell migration and metastasis in nasopharyngeal carcinoma), there is currently no evidence that ARHGAP42-AS1 itself is a directly druggable therapeutic target or that drugs have been developed to target this lncRNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ARHGAP42 antisense RNA 1 (ARHGAP42-AS1).